Tom Sutherland

Appearances

CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. TWO YEAR RESULTS OF THE STRIDENT RANDOMIZED CONTROLLED TRIAL.
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Speakers
Julien Schulberg
Amy Hamilton
Bronte Holt
Grace Lovett
Tom Sutherland
Alyson Ross
Sara Vogrin
Presenters
Emily Wright
Michael Kamm